Super-enhancers in hepatocellular carcinoma: regulatory mechanism and therapeutic targets
- PMID: 39773719
- PMCID: PMC11706108
- DOI: 10.1186/s12935-024-03599-5
Super-enhancers in hepatocellular carcinoma: regulatory mechanism and therapeutic targets
Abstract
Super-enhancers (SEs) represent a distinct category of cis-regulatory elements notable for their robust transcriptional activation capabilities. In tumor cells, SEs intricately regulate the expression of oncogenes and pivotal cancer-associated signaling pathways, offering significant potential for cancer treatment. However, few studies have systematically discussed the crucial role of SEs in hepatocellular carcinoma (HCC), which is one of the most common liver cancers with late-stage diagnosis and limited treatment methods for advanced disease. Herein, we first summarize the identification methods and the intricate processes of formation and organization of super-enhancers. Subsequently, we delve into the roles and molecular mechanisms of SEs within the framework of HCC. Finally, we discuss the inhibitors targeting the key SE-components and their potential effects on the treatment of HCC. In conclusion, this review meticulously encapsulates the distinctive characteristics of SEs and underscores their pivotal roles in the context of hepatocellular carcinoma, presenting a novel perspective on the potential of super-enhancers as emerging therapeutic targets for HCC.
Keywords: Hepatocellular carcinoma; Super-enhancer; Therapeutic targets.
© 2024. The Author(s).
Conflict of interest statement
Declarations. Ethics approval and consent to participate: Not applicable. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.
Figures




Similar articles
-
The super-enhancer repertoire in porcine liver.J Anim Sci. 2023 Jan 3;101:skad056. doi: 10.1093/jas/skad056. J Anim Sci. 2023. PMID: 36800318 Free PMC article.
-
Aberrant Super-Enhancer Landscape in Human Hepatocellular Carcinoma.Hepatology. 2019 Jun;69(6):2502-2517. doi: 10.1002/hep.30544. Epub 2019 Apr 16. Hepatology. 2019. PMID: 30723918
-
Targeting super enhancers for liver disease: a review.PeerJ. 2023 Jan 27;11:e14780. doi: 10.7717/peerj.14780. eCollection 2023. PeerJ. 2023. PMID: 36726725 Free PMC article. Review.
-
Super-enhancers and novel therapeutic targets in colorectal cancer.Cell Death Dis. 2022 Mar 11;13(3):228. doi: 10.1038/s41419-022-04673-4. Cell Death Dis. 2022. PMID: 35277481 Free PMC article. Review.
-
Super-enhancer-associated circPVT1 promotes malignancy of hepatocellular carcinoma via YBX1-mediated RRM2 activation.Cancer Lett. 2024 Dec 16;611:217395. doi: 10.1016/j.canlet.2024.217395. Online ahead of print. Cancer Lett. 2024. PMID: 39694225
Cited by
-
Electroactive Fe3O4/α-Fe2O3@Au nanocomposites driven label-free electrochemical aptasensor with magnetic self-assembly for rapid quantification of alpha-fetoprotein.Mikrochim Acta. 2025 May 17;192(6):361. doi: 10.1007/s00604-025-07173-2. Mikrochim Acta. 2025. PMID: 40381048
-
Integrated Single-Cell Analysis Dissects Regulatory Mechanisms Underlying Tumor-Associated Macrophage Plasticity in Hepatocellular Carcinoma.Genes (Basel). 2025 Jul 12;16(7):817. doi: 10.3390/genes16070817. Genes (Basel). 2025. PMID: 40725473 Free PMC article.
References
-
- Rinaldi L, Guarino M, Perrella A, Pafundi PC, Valente G, Fontanella L, Nevola R, Guerrera B, Iuliano N, Imparato M, et al. Role of Liver Stiffness Measurement in Predicting HCC occurrence in direct-acting antivirals setting: a real-life experience. Dig Dis Sci. 2019;64(10):3013–9. - PubMed
-
- Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301–14. - PubMed
-
- Villanueva A. Hepatocellular Carcinoma. N Engl J Med. 2019;380(15):1450–62. - PubMed
-
- Sugawara Y, Hibi T. Surgical treatment of hepatocellular carcinoma. Biosci Trends. 2021;15(3):138–41. - PubMed
-
- Vibert E, Schwartz M, Olthoff KM. Advances in resection and transplantation for hepatocellular carcinoma. J Hepatol. 2020;72(2):262–76. - PubMed
Publication types
Grants and funding
- 82300661/the National Natural Science Foundation of China
- 2308085QH246/the Natural Science Foundation of Anhui province
- XJ201925/Scientific Research of BSKY from Anhui Medical University
- KJ2021A0205/the Natural Science Foundation of the Anhui Higher Education Institutions
- 2022xkjT013/Basic and Clinical Cooperative Research Promotion Program of Anhui Medical University
LinkOut - more resources
Full Text Sources